KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

ZADITEN SYRUP

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

 

GENERIC NAME:

KETOTIFEN

 

MANUFACTURER:

NOVARTIS PHARMA

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Conjunctivitis, allergic

Itching, secondary to allergic conjunctivitis

 

SIDE EFFECTS:

Flu

respiratory infection

Cystitis

erythema multiforme

hepatitis

seizures

Weight gain

Abdominal pain

central nervous system (CNS) stimulation

dizziness

dryness of mouth

epistaxis

increased appetite

sedation

skin rash

sleep disturbance

swelling of eyelids

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

>> Diabetes mellitus

should be taken into consideration; use ketotifen with caution if taking an oral antidiabetic agent )

>> Epilepsy

 

ADULT DOSE:

Asthma, atopic (prophylaxis) - Oral, 5 mL (1 mg) twice daily, in the morning and evening.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Asthma, atopic (prophylaxis) - Infants and children 6 months to 3 years of age: Oral, 0.25 mL (50 mcg or 0.05 mg) per kg of body weight twice daily, in the morning and evening. Children older than 3 years of age: See Usual adult and adolescent dose. 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT